{"id":288666,"date":"2026-10-06T10:06:16","date_gmt":"2026-10-06T04:36:16","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=288666"},"modified":"2026-10-06T10:06:16","modified_gmt":"2026-10-06T04:36:16","slug":"rpg-life-sciences-vs-senores-pharma-vs-rubicon-research","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/rpg-life-sciences-vs-senores-pharma-vs-rubicon-research\/","title":{"rendered":"RPG Life Sciences vs Senores Pharma vs Rubicon Research: Which Stock Should You Track"},"content":{"rendered":"

RPG Life Sciences PE 39.98, mkt cap Rs 4,784 crore. Senores Pharmaceuticals PE 46.56, mkt cap Rs 6,092 crore. Rubicon Research PE 92.46, mkt cap Rs 26,645 crore.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

RPG Life Sciences vs Senores Pharmaceuticals vs Rubicon Research is a side-by-side comparison of three companies from the Pharma and Life Sciences space. On this comparison, RPG Life Sciences carries a market capitalisation of about Rs 4,784 crore against Rs 6,092 crore for Senores Pharmaceuticals and Rs 26,645 crore for Rubicon Research, with return on equity of 19.03%, 12.36% and 19.14% respectively. Each company’s numbers are presented here without a declared better pick, since the right stock depends on an investor’s own criteria.<\/p>\n<\/div>\n

RPG Life Sciences vs Senores Pharmaceuticals vs Rubicon Research starts with the core numbers most investors compare within the Pharma and Life Sciences segment: market capitalisation, valuation multiples, profitability and dividend yield. Figures below are sourced as of September 2026 and will shift with daily price moves.<\/p>\n

All three names sit in the Pharma and Life Sciences bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n